Almac Announces Further Expansion and 229 New Jobs
Following the success of one of its key client partnered products, Craigavon-based pharmaceutical company Almac, has announced the commercial manufacturing expansion. Together with the recent completion of a new non-GMP drug development facility at the Craigavon site this dual expansion represents a total investment of £13.7 million, which includes some financial support from Invest Northern Ireland. During the next 3 years up to 229 jobs will be created across both projects.
The product, a laxative drug, which is contract manufactured by Almac, has recorded robust sales growth year on year throughout the UK and Europe. With existing facilities at full capacity and further demand forecast in a number of new markets Almac decided to focus all production in Northern Ireland with additional equipment and resources in Craigavon. The investment will deliver blending equipment, an automated packing and integrated cartoning line, which will enable high volume bulk commercial manufacturing scheduled to begin in November 2013.
Also at the Craigavon site Almac is experiencing growth through the creation of a new 13,400 sq ft formulation development facility and analytical laboratories. This facility focuses on the development of tablet and capsule formulations for new drugs that are in the early stages of development and have not yet reached the market. The new 'non-GMP' facility will enable greater speed in formulation and process development, by creating an environment where development work can be progressed quickly and efficiently, free of many of the constraints usually associated with drug manufacturing.
Graeme McBurney, President & Managing Director of the business unit explains: “The laxative product has been a great success in the UK and increasingly in European markets. The marketing and promotion of the product by our contract customer has been very effective and significant growth potential in several new territories such as China has been identified. Centralizing and expanding our production in Craigavon will mean more cost effective manufacturing and optimal quality control and distribution.”
“We are also delighted to see the completion of the new non-GMP facility on site which, alongside Almac’s existing GMP capability, will enable us to operate with improved speed and efficiency in the early stages of projects. This latest addition makes Almac a much more attractive proposition to international clients who seek streamlined, one stop drug development solutions.”
Enterprise Minister Arlene Foster said: “This investment is good news for Craigavon and will reinforce Northern Ireland’s position in the wider life sciences sector. The 229 new jobs will deliver almost £5.5 million annually in salaries, bringing an important and positive economic boost which will benefit local people.”
“Almac has a reputation for excellence in the international pharmaceuticals sector and today’s announcement will ensure that it remains in a competitive position and can continue to meet the needs of its global client base.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance